This is Part 4 of our series on peptides. We’ve covered what peptides are, how they work, and the GLP-1 medications everyone’s asking about. Now the practical part: with these drugs sold everywhere from clinics to sketchy websites, how do you tell what you’re actually getting — and how do you protect yourself?
Three Very Different Things Called “The Same Drug”
When someone says they’re “on semaglutide” or “taking tirzepatide,” they could mean one of three quite different products:
| What it is | Examples | FDA oversight |
|---|---|---|
| FDA-approved product | Wegovy, Zepbound, Ozempic, Mounjaro | Reviewed and monitored for safety, quality, and effectiveness |
| Compounded version | Custom-mixed semaglutide/tirzepatide from a pharmacy | Not FDA-reviewed before sale; legal only in narrow situations |
| Unregulated / “research” product | Powders and vials sold online “for research use only” | None — not intended or tested for human use |
They can contain the same active ingredient on paper. What differs is everything around it: whether the dose is accurate, whether it’s pure, whether anyone checked.
What “Compounding” Actually Is — and Why GLP-1 Compounding Is Ending
Compounding is a legitimate, long-standing practice: a licensed pharmacy custom-makes a medication for a specific patient who can’t use the standard product — say, someone who needs a different dose or has an allergy to an inactive ingredient. That role isn’t going away.
What grew during the GLP-1 boom was something different: mass-scale compounding of semaglutide and tirzepatide, sold at telehealth-subscription scale simply because it was cheaper than the brand-name drugs. That was permitted mainly because the FDA had declared the approved products in shortage. Those shortages have now been resolved — and with them, the legal basis for mass compounding has largely disappeared.
Where the rules stand in 2026
- The FDA has declared the semaglutide and tirzepatide shortages over.
- Compounding these drugs simply because it’s cheaper — at telehealth scale, with no individual medical reason — is no longer permitted.
- Narrow, patient-specific compounding can still be legal when a prescriber documents a genuine clinical need the commercial product can’t meet.
- In April 2026 the FDA proposed formally removing these drugs from the outsourcing-facility bulk list, a step expected to be finalized later this year.
Why the FDA Has Been Cracking Down
This isn’t red tape for its own sake. The safety record of mass-compounded and unregulated GLP-1s is genuinely concerning:
- The FDA has sent warning letters to dozens of telehealth companies — over 100 in 2025, and more waves in 2026 — for marketing compounded GLP-1s with false or misleading claims, including implying they’re equivalent to the approved drugs.
- The maker of the brand-name products reported that testing of some compounded injectable semaglutide found impurities as high as 86%.
- Regulators have linked compounded semaglutide to hundreds of adverse-event reports, including hospitalizations and deaths, with dosing errors a major factor — patients drawing up the wrong amount from multi-dose vials.
The pattern is consistent: the danger isn’t usually the molecule itself, it’s everything that can go wrong when quality control, accurate dosing, and medical supervision are missing.
How to Tell What You’re Actually Getting
You don’t need a chemistry degree to protect yourself — just a few questions. Favor a source that can answer “yes” to these:
Green flags
- It’s an FDA-approved, brand-name product (Wegovy, Zepbound, Ozempic, Mounjaro) in its original manufacturer packaging and pen.
- It was prescribed after a real evaluation by a licensed provider who took your history.
- There’s follow-up — dose adjustments, side-effect checks, someone to call.
- The pharmacy is licensed and named.
Red flags
- Sold without a prescription or any medical evaluation.
- Labeled “for research use only” or “not for human consumption.”
- Marketed as “the same as” a brand-name drug for a fraction of the price.
- Vague about the pharmacy, the source, or what’s actually in the vial.
- Comes as a powder you’re expected to mix or measure yourself.
Frequently Asked Questions
Is compounded semaglutide legal in 2026?
Only in narrow cases. Now that the FDA considers the shortage resolved, mass compounding of semaglutide simply to sell it cheaply is no longer permitted. Patient-specific compounding can still be legal when a prescriber documents a genuine clinical need the approved product can’t meet — but that’s a specific medical exception, not a discount channel.
Is compounded medication always dangerous?
No — traditional, patient-specific compounding by a licensed pharmacy serves real needs. The concern is the mass-produced and unregulated GLP-1 market that grew during the shortage, where quality and dosing haven’t been verified the way they are for approved products.
How do I know if my telehealth GLP-1 is legitimate?
Look at what you’re actually shipped. An FDA-approved product arrives as a brand-name pen in manufacturer packaging. If you’re sent a generic vial of “semaglutide” to draw up yourself, that’s a compounded or unregulated product — ask the provider directly what it is and where it’s made.
What about “research peptides” like BPC-157?
Those are a step further out — not FDA-approved for human use at all, and typically sold “for research use only.” We’ll cover that landscape in the final part of this series.
It’s so much cheaper online — is it really worth the risk?
Cost is a real concern, and worth an honest conversation with a provider about approved options and insurance coverage. But the savings on an unverified product can come at the price of unknown purity and dosing errors — the very problems tied to the reported hospitalizations. Cheaper isn’t a bargain if you can’t trust what’s in it.
The Honest Version Is the Safe One
Our take across this whole series has been the same: the medicine can be legitimate and effective — the danger comes from cutting out quality control and medical supervision. If you’re considering a GLP-1 medication, AG Urgent Care offers supervised GLP-1 weight-loss and diabetes care across Brooklyn and Queens using FDA-approved medications — with a real evaluation and real follow-up. Walk in or check in online.
Coming Up Next
In the final part, we look at the research-peptide landscape — BPC-157, sermorelin, and the others generating buzz — and separate what’s actually known from the marketing.
Medical Disclaimer: This article is for general informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation, nor an endorsement of any specific product. Regulatory status is subject to change; confirm current information with official FDA sources and a licensed healthcare provider. Never start, stop, or purchase any medication or peptide product without consulting a qualified clinician. In a medical emergency, call 911.